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Many pathogenic microorganisms evade host immunity through extensive sequence variability in a protein region
targeted by protective antibodies. In spite of the sequence variability, a variable region commonly retains an
important ligand-binding function, reflected in the presence of a highly conserved sequence motif. Here, we analyze
the limits of sequence divergence in a ligand-binding region by characterizing the hypervariable region (HVR) of
Streptococcus pyogenes M protein. Our studies were focused on HVRs that bind the human complement regulator C4b-
binding protein (C4BP), a ligand that confers phagocytosis resistance. A previous comparison of C4BP-binding HVRs
identified residue identities that could be part of a binding motif, but the extended analysis reported here shows that
no residue identities remain when additional C4BP-binding HVRs are included. Characterization of the HVR in the M22
protein indicated that two relatively conserved Leu residues are essential for C4BP binding, but these residues are
probably core residues in a coiled-coil, implying that they do not directly contribute to binding. In contrast,
substitution of either of two relatively conserved Glu residues, predicted to be solvent-exposed, had no effect on C4BP
binding, although each of these changes had a major effect on the antigenic properties of the HVR. Together, these
findings show that HVRs of M proteins have an extraordinary capacity for sequence divergence and antigenic
variability while retaining a specific ligand-binding function.
Citation: Persson J, Beall B, Linse S, Lindahl G (2006) Extreme sequence divergence but conserved ligand-binding specificity in Streptococcus pyogenes M protein. PLoS Pathog
2(5): e47. DOI: 10.1371/journal.ppat.0020047
Introduction
Sequence variability is a common feature in surface
proteins of pathogenic microorganisms. Such variability
may confer increased ﬁtness because it allows the pathogen
to use alternative receptors or allows infection of different
tissues or even different species [1–5]. However, in most cases
the variability probably reﬂects antigenic variation, which
allows the pathogen to evade protective immunity in an
infected host [6].
The sequence variability that gives rise to antigenic
variation may be very extensive and represents an apparent
paradox because the variable protein must retain an
important function in spite of the variability. To explain
this apparent contradiction, it is commonly assumed that
conservation of a limited number of residues is sufﬁcient to
promote correct protein folding and/or to confer a speciﬁc
function [7], while other residues may vary and cause
changes in antigenic properties of the protein. For
example, the very variable hemagglutinin of the inﬂuenza
virus has a few highly conserved residues that are located in
the receptor-binding pocket [8–10]. Similarly, the CD36-
binding region of the Plasmodium falciparum protein PfEMP1
varies extensively in sequence, but several conserved
residues were predicted to be important for binding [11].
In contrast, we show here that the hypervariable region
(HVR) in streptococcal M protein, a major bacterial
virulence factor, retains ability to speciﬁcally bind a human
protein ligand, although different HVRs completely lack
residue identities.
The Gram-positive bacterium Streptococcus pyogenes (group A
streptococcus) is a major human pathogen that causes a
variety of diseases, including acute pharyngitis and the
streptococcal toxic shock syndrome [12]. The surface-local-
ized M protein, which is the most extensively studied
virulence factor of S. pyogenes, is a dimeric coiled-coil that
inhibits phagocytosis and exhibits antigenic variation due to
the ;50-residue N-terminal HVR [13,14]. The HVR is stable
within a strain of S. pyogenes, allowing the identiﬁcation of
;120 different M types [15], although limited sequence
variability is occasionally observed between clinical isolates
of the same M type. Thus, the number of known M types is
small compared to the large number of possible sequence
variants, suggesting that these M types have been selected
because of their superior ﬁtness.
In many M proteins, the HVR speciﬁcally binds a human
complement inhibitor, the plasma protein C4b-binding
protein (C4BP), which prevents complement deposition on
the bacterial surface and allows the bacteria to evade
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prevent binding of C4BP promote phagocytosis [20,21], the
sequence divergence among C4BP-binding HVRs probably
reﬂects selection during evolution of antigenic variants that
retain ability to bind C4BP. This argument implies that severe
limitations exist on possible sequences in the HVR, a
conclusion supported by extensive sequence analysis [22,23].
The C4BP-binding HVRs are distinct ligand-binding
domains that bind to the same region in C4BP and probably
have similar structures [18,24–26]. Nevertheless, comparison
of different C4BP-binding HVRs only allowed the identiﬁca-
tion of three amino acid residue identities [18,25]. It seemed
possible that these three identities were part of a binding
motif, but we hypothesized that not even these residues would
be required for binding of C4BP. To analyze this hypothesis
we used a large collection of clinical S. pyogenes isolates and
found that C4BP-binding HVRs indeed lack a common
sequence motif. Thus, M proteins have an extraordinary
capacity for sequence divergence while retaining the ability
to speciﬁcally bind a ligand. We also present evidence that
even a single amino acid change that does not affect C4BP-
binding may cause a major antigenic change in an HVR,
providing a molecular basis for the appearance of new M
types through gradual accumulation of mutations.
Figure 1. The Binding Site for Human C4BP in the Hypervariable Region (HVR) of M Protein
(A) Schematic representation of C4BP bound to the HVR of an M protein, a dimeric coiled-coil. The most common form of C4BP has seven identical a-
chains and one short b-chain. Both chains are composed of CCP modules, as indicated. The binding site for M protein in C4BP is located in the CCP1–2
region of the a-chain [17,24,47].
(B) Multiple sequence alignment of HVRs that bind C4BP. The five upper sequences are from [25]. Three residues that are identical in these five
sequences are boxed. PrtH is a second M protein expressed by certain M1 strains [35]. The lower part of the alignment shows the HVRs of M4.1 and
M114, characterized in this paper. The vertical hatched lines, corresponding to residues 1–39 in M22, indicate the region used to generate the logo in
Figure 5A.
(C) Construction of fusion proteins derived from the M22 and M5 proteins. An N-terminal region derived from M22 was fused to the C-terminal part of
M5 (residues 104–450 of M5). The fusion proteins contain the Fg-binding B-repeat region of M5.
(D) Schematic representation of the N-terminal region of different fusion proteins. The sequence of the N-terminal region of M22 is given at the top.
Asterisks indicate the position of residues L28, E31, and D40 in M22 (corresponding to the three boxed residues in [B]). The ability of the fusion proteins
to bind C4BP, indicated to the right, is based on the results shown in (E).
(E) Ability of fusion proteins to bind C4BP. The fusion proteins (D) are referred to as M22
57–M5, etc. Whole-cell lysates of E. coli strains, expressing the
indicated proteins from genes carried on pBR322, were analyzed by Western blot using Fg or C4BP as the probe. The strain expressing M5 was used as a
negative control. The control blot with Fg showed that the proteins were expressed in E. coli. The presence of double bands probably reflects
incomplete processing of signal peptides in E. coli and/or intracellular degradation of M protein in this heterologous host.
DOI: 10.1371/journal.ppat.0020047.g001
PLoS Pathogens | www.plospathogens.org May 2006 | Volume 2 | Issue 5 | e47 0443
Sequence Divergence in M Proteins
Synopsis
Many pathogens have evolved mechanisms to evade host
immunity. In one such mechanism, the sequence of a surface
protein varies among different strains of a pathogen. This sequence
variability represents an apparent paradox, because the variable
protein must retain an important function. The authors studied this
problem in Streptococcus pyogenes, a major human pathogen. The
surface-localized M protein of this bacterium varies extensively in
sequence between bacterial strains, allowing immune escape.
Nevertheless, the most variable part of the M protein commonly
binds a human plasma protein. By hijacking this human protein the
bacteria evade attack by complement an important part of the
innate immune system. Comparison of the ligand-binding region in
different M proteins showed that these regions lack a shared amino
acid sequence motif. Thus, a variable protein can retain a ligand-
binding function in the absence of a conserved binding motif.
Evidence is also presented that a single amino acid change in the
variable region may cause a major antigenic change, providing a
selective advantage for the bacteria. Together, these data bear
witness to the extraordinary ability of pathogens to escape host
immunity, without losing ability to cause disease.Results
The C4BP-Binding Region in the M22 Protein
Five C4BP-binding HVRs that have been characterized
previously [18,25] are aligned in the upper part of Figure 1B
and the three amino acid identities in these sequences of ;50
residues are boxed. In spite of the sequence divergence, the
alignment of these sequences was clear-cut, as shown by
pairwise comparisons. The three identities correspond to
L28, E31, and D40 in M22, an extensively studied C4BP-
binding M protein which we used as model protein
[18,20,21,24]. Of note, M22 is one of the most common
serotypes among strains of S. pyogenes isolated in different
parts of the world [27–29], making the M22 protein an
attractive model protein.
A region comprising the 52 N-terminal residues in M22 is
sufﬁcient for C4BP binding [25]. To analyze whether the C-
terminal part of this region, and in particular the D40
residue, is required for binding, we constructed a series of
fusion proteins in which N-terminal regions of different
length, derived from M22, were fused to the C-terminal part
of an M protein that does not bind C4BP, the M5 protein
(Figure 1C and 1D). The region derived from M5, comprising
residues 104–450, had the same length in each construct and
included a ﬁbrinogen (Fg)–binding region, which was used for
detection of the fusion proteins. After expression in
Escherichia coli, the fusion proteins were analyzed by Western
blot for ability to bind Fg and C4BP (Figure 1E). Constructs
that included 57, 40, or 39 residues from M22 showed equally
good binding of C4BP, while a construct that only included
31 residues from M22 did not bind. Of note, the ability of the
M22
39–M5 protein to bind C4BP was not due to the
contribution of an Asp residue, corresponding to D40 in
M22, by the M5 fusion partner because the ﬁrst residue in the
part derived from M5 was a Leu. These data indicate that a
region comprising the 39 N-terminal amino acids in M22 is
sufﬁcient for binding of C4BP. This region only includes two
of the identities, L28 and E31, with the other previously
studied C4BP-binding regions (Figure 1B).
Characterization of Additional M Proteins Demonstrates
that C4BP-Binding Regions Completely Lack Residue
Identities
We hypothesized that not even the two residues corre-
sponding to L28 and E31 in M22 are conserved in all C4BP-
binding M proteins. To analyze this hypothesis, we screened a
large number of reference S. pyogenes strains for ability to bind
C4BP and analyzed the M protein sequence in strains that
were able to bind C4BP. The strains used were either opacity
factor–positive (OF
þ)o rO F
 , the two major subgroups of S.
pyogenes strains, and they represented most known M types
and some subtypes (Figure 2). The sequence of HVRs was
analyzed by using information available from epidemiological
studies (http://www.cdc.gov/ncidod/biotech/strep/doc.htm).
To ensure that strains analyzed for C4BP-binding ex-
pressed M protein, they were ﬁrst tested for ability to bind Fg,
a characteristic property of clinical isolates expressing
Figure 2. Binding of Human C4BP to S. pyogenes Strains of Different M Types
Strains of the M types indicated were analyzed for ability to bind radiolabelled C4BP. Upper panel: OF
þstrains. Lower panel: OF
 strains. Only strains that
bound Fg, as determined in parallel tests, were used for the analysis because binding of Fg is a characteristic property of S. pyogenes isolates expressing
members of the M protein family. Binding is expressed as percent of added radioactivity. The threshold for binding of C4BP was set at  10% binding
(dashed line). Background binding to an M-negative strain (;3%) has been subtracted. All strains were tested at least twice, with duplicate samples, and
the results were highly reproducible. For each strain, data from one experiment are shown. The data include binding data for one allelic variant per M
type, except that data for both M4 and M4.1 are included. For strains of some M types, several allelic variants were tested and in most cases these strains
did not differ in ability to bind C4BP (unpublished data).
DOI: 10.1371/journal.ppat.0020047.g002
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Sequence Divergence in M Proteinsmembers of the M protein family [13,14,30]; only Fg-binding
strains were analyzed for ability to bind C4BP. This step was
included because a strain of S. pyogenes propagated in the
laboratory may occasionally lose ability to express M protein
[13]. Background binding to an M-negative strain was
subtracted and the threshold for binding of C4BP was set at
 10% binding. In this analysis, binding of C4BP was seen for
all 47 OF
þ strains studied and for 80% of the 54 OF
– strains
(Figure 2). These results extend ﬁndings made in previous
studies [16,31] and indicate that binding of C4BP is a very
common property among strains of S. pyogenes. Interestingly,
C4BP binding was observed for all tested strains of the
recently recognized M types M94–M124, which include both
OF
þ and OF
  strains [15,32]. Based on preliminary sequence
analysis of HVRs in C4BP-binding strains, our work was
focused on two OF
þ strains expressing the M114 and M4.1
proteins, respectively. The sequences of the corresponding
two HVRs are aligned with the ﬁve previously studied HVRs
in the lower part of Figure 1B.
The M114 protein was chosen for further study because the
residue in M114 corresponding to E31 in M22 is a helix-
breaking Gly, and because M114 is a common type among
strains causing invasive disease (see [27], where M114 was
referred to as st2967). The M4.1 protein, which is a subtype of
M4, was chosen for further study because it has a Phe at the
position corresponding to L28 in M22. Of note, even a
conservative change from Leu to Phe may have important
effects on protein structure and function, as observed for the
positive gene regulator PrfA of Listeria monocytogenes [33] and
the eukaryotic protein calmodulin [34].
Although it seemed likely that the HVRs in the M4.1 and
M114 proteins were responsible for the ability of the
corresponding strains to bind C4BP, this was not obvious
because some S. pyogenes strains express a second M or M-like
protein that binds C4BP. For example, some strains of
serotype M1 and M18 express an M protein that does not
bind C4BP, and also express an M-like C4BP-binding protein
[18,35,36]. Moreover, it could not be excluded that the ability
of the M4.1 and M114 strains to bind C4BP was caused by a
surface structure unrelated to M proteins. Thus, it was
essential to demonstrate that the HVRs of the M4.1 and M114
proteins promoted binding of C4BP.
Fusion proteins were constructed in which the HVR of
M4.1 or M114 was combined with the C-terminal part of M5,
generating the M4.1–M5 and M114–M5 proteins. Preliminary
analysis showed that these two fusion proteins were able to
bind C4BP after expression in E. coli, demonstrating that the
HVRs of M4.1 and M114 indeed bind C4BP (unpublished
data). To analyze C4BP binding in a physiological setting and
to allow quantitative analysis, the two fusion proteins were
characterized after expression in S. pyogenes using genes
expressed from a shuttle vector in an M-negative S. pyogenes
strain (Figure 3). Expression of the fusion proteins on the
bacterial surface was veriﬁed by analysis with antiserum to
the conserved C-repeat region of M5 (anti–M5-C). Strains
expressing the C4BP-binding fusion protein M22
57–M5 [18]
or the nonbinding M5 protein served as positive controls for
reactivity with the antibodies, while the M-negative strain
DM5 served as negative control. The results (Figure 3A) show
that the M4.1–M5 and M114–M5 fusion proteins were
expressed on the streptococcal surface at the same level as
the M22
57–M5 protein. The somewhat lower surface expres-
sion observed for M5 might be due to a weaker promoter in
the corresponding gene. When analyzed for ability to bind
C4BP, the streptococcal strains expressing M4.1–M5 and
M114–M5 not only showed binding, but bound C4BP even
better than the control strain expressing the M22
57–M5
protein (Figure 3B). These data show that the HVRs of the
M4.1 and M114 proteins represent C4BP-binding regions
similar to those previously described [18].
From the analysis of M4.1 and M114, it follows that C4BP-
binding HVRs in M proteins completely lack residue
identities (Figure 1B). Thus, the HVR of M protein has an
extraordinary capacity to tolerate sequence divergence while
retaining the ability to bind C4BP.
The HVR of the M114 Protein Is a Distinct C4BP-Binding
Domain
Previous studies with synthetic peptides, derived from the
HVRs of the M2, M4, and M22 proteins, showed that these
HVRs represent distinct domains that bind with high
speciﬁcity to the same region in C4BP [25]. Importantly,
binding of C4BP to such a peptide is strongly enhanced by
peptide dimerization via a C-terminal cysteine residue
[25,37]. This ﬁnding may be explained by the demonstration
that the C4BP-binding HVRs probably have dimeric coiled-
coil structure [26] and suggests that the coiled-coil must be
stabilized by a disulphide bond in the peptides, but not in the
intact M proteins. Because the HVR of M114 contains a helix-
breaking Gly residue, suggesting that it might have properties
different from the other HVRs, a dimerized synthetic peptide
derived from this HVR was analyzed with regard to binding
speciﬁcity, binding site in C4BP, and secondary structure and
stability. The binding properties of the M4.1 HVR were not
Figure 3. The HVRs of M4.1 and M114 Bind C4BP
Fusion proteins, derived from the HVR of M4.1 or M114 and the C-
terminal part of M5, were expressed in the M-negative strain S. pyogenes
DM5 using genes carried on plasmid pLZ12Spec. Controls included a
strain expressing the C4BP-binding fusion protein M22
57–M5, a strain
expressing the non–C4BP-binding M5 protein, and the M-negative strain
DM5.
(A) Surface expression analyzed with rabbit antibodies directed against
the C-repeat region of M5. Bound antibodies were detected with
radiolabelled protein A. Binding of protein A to the M22
57–M5 strain,
incubated with antiserum diluted 310
2, was defined as 100%. The M5-
negative strain DM5 served as negative control.
(B) Binding of radiolabelled C4BP. Binding at the highest bacterial
concentration to the control expressing M2257–M5 was defined as 100%.
The non–C4BP-binding M5 strain served as negative control. All data in
(A) and (B) are based on three separate experiments with duplicate
samples, and are presented as means 6 SD.
DOI: 10.1371/journal.ppat.0020047.g003
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Sequence Divergence in M Proteinsstudied further because it was not possible to synthesize a
peptide corresponding to this HVR.
The synthetic peptide derived from M114, comprising the
52 N-terminal residues in the mature form of M114 and
designated M114-N, was found to bind C4BP (unpublished
data). The speciﬁcity of the binding was analyzed by afﬁnity
chromatography. For this purpose, whole human serum was
applied to a column containing immobilized M114-N and
bound protein was eluted and analyzed by SDS-PAGE [25,37]
(Figure 4A). Columns containing peptides derived from the
C4BP-binding HVR of M22 or the nonbinding HVR of M5
(peptides M22-N and M5-N) were used as positive and
negative controls, respectively. The eluates from the M114-
N and M22-N columns contained a single major polypeptide,
which was identiﬁed as the C4BP a-chain, while no protein
was retained on the M5-N column. Because C4BP has a serum
concentration of ;200 mg/l and therefore represents ,0.5%
of all protein in serum [38], this result demonstrates that the
M114-N peptide binds C4BP with high speciﬁcity.
To analyze whether M114 binds to the same region in C4BP
as other C4BP-binding M proteins, the M114-N peptide was
tested for ability to inhibit the interaction between the C4BP-
binding M22 protein and immobilized C4BP (Figure 4B). The
C4BP-binding M22-N peptide and the nonbinding M5-N
peptide were used as positive and negative controls,
respectively. The M114-N peptide inhibited the interaction,
but was a less-efﬁcient inhibitor than the M22-N peptide,
possibly because M114-N binds with lower afﬁnity. This
inhibition was not unspeciﬁc because the binding of IgA to
M22 [39] was not inhibited by M114-N (unpublished data).
These results indicate that M114 binds to a site in C4BP that
is overlapping, if not identical, with that used by M22.
Analysis of M114-N by circular dichroism spectroscopy
indicated that the secondary structure of this peptide is
similar to that of M4-N and M22-N (unpublished data).
Moreover, the melting temperature of M114-N was lower
than for M4-N and M22-N, possibly reﬂecting lower stability
of this peptide because of the presence of the helix-breaking
Gly residue (unpublished data).
A previous immunological analysis of C4BP-binding
synthetic peptides derived from the HVRs in M2, M4, and
M22 showed that they lack cross-reactivity, although they
have similar binding properties [25]. In agreement with these
ﬁndings, M114-N was not recognized by antibodies to the
HVRs of the M4 and M22 proteins, but showed limited cross-
reactivity with the HVR of the M2 protein, to which M114-N
is most closely related (unpublished data). These results
conﬁrm that C4BP-binding HVRs show great antigenic
variability.
Together, the analysis of M114-N indicates that this
peptide has properties similar to other peptides derived
from C4BP-binding HVRs in spite of the presence of a Gly
residue in M114-N.
Sequence Analysis and Site-Specific Mutagenesis
Although the seven C4BP-binding HVRs described above
exhibit extreme sequence divergence (Figure 1B), a sequence
logo of these HVRs shows that the region comprising residues
21–31 (numbering based on M22) is less variable than the
other parts of the HVRs (Figure 5A). This is not surprising
because some residues may be expected to be more
important than other ones for structure and/or ligand
binding, although no single residue is absolutely required
for ability to bind C4BP.
The conserved parts of M proteins are known to be dimeric
coiled-coils [40,41], but it has remained unclear whether the
HVRs also form coiled-coils. Indeed, a previous computa-
tional analysis suggested that the HVRs may adopt helix-turn-
helix conformation [25]. However, the recent nuclear
magnetic resonance study by Andre ´ et al. [26] indicates that
the HVRs do have coiled-coil conformation. This situation
made it of interest to analyze whether the distribution of
residues in the alignment region represented in the logo was
compatible with coiled-coil structure in the HVRs. A coiled-
coil is characterized by a seven-residue periodicity in which
the residues are designated a–g. Residues at positions a and d
most often are hydrophobic and constitute the core of the
coiled-coil, while the other residues are solvent-exposed [42]
(Figure 5B). However, in M or M-like proteins, the heptad
patterns often show a nonoptimal distribution of residues
[41,43], and in some M proteins position a is commonly
occupied by an Asn residue [40]. The distribution of amino
acid residues over the aligned region ﬁts well with the
hypothesis that the less variable region corresponding to
residues 21–31 in M22 is part of a coiled-coil.
We used site-speciﬁc mutagenesis of M22 to analyze the
role of different residues for C4BP binding. These studies
were focused on the four relatively conserved residues L21,
E24, L28, and E31, which are located within the predicted
coiled-coil region (Figure 5A and 5B). The L21 and L28
residues are predicted to be core residues that occupy
position d in the coiled-coil, while residues E24 and E31 are
predicted to be solvent-exposed residues occupying position
g. Each of these residues was changed to Ala and the four
Figure 4. Characterization of the C4BP-Binding HVR in M114
(A) The HVR of M114 is a distinct protein domain that binds C4BP with
high specificity. A dimerized synthetic peptide, derived from the 52 N-
terminal residues in M114 and designated M114-N, was immobilized in a
column. Whole human serum was passed through the column, which
was washed and eluted. Control columns contained the C4BP-binding
M22-N peptide or the nonbinding M5-N peptide. The eluates, and
human serum, were analyzed by SDS-PAGE, as indicated. The ;70 kDa
polypeptide present in the eluates from the M22-N and M114-N columns
was identified as the C4BP a-chain by Western blot analysis with specific
antiserum (not shown).
(B) The M114 and M22 proteins bind to the same region in C4BP. The
peptides indicated were used to inhibit the binding of radiolabelled M22
protein to C4BP immobilized in microtiter wells. Data from three
separate experiments with duplicate samples, presented as means 6 SD.
DOI: 10.1371/journal.ppat.0020047.g004
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Sequence Divergence in M Proteinsmutant M22 proteins were expressed in S. pyogenes. To analyze
whether the mutant proteins were expressed normally on the
bacterial surface, the strains were analyzed for reactivity with
antibodies against the conserved C-repeat region in M22 and
for ability to bind human IgA, which speciﬁcally binds to M22
[39]. The analysis with anti-C serum was performed with
antibodies raised in the rat, because rabbit antibodies show
Fc-reactivity with M22 [39]. Analysis with this rat serum
showed that the mutant proteins were present on the
streptococcal surface in the same amounts as the wild-type
protein expressed by the positive control (Figure 5C), and
similar results were obtained in binding analysis with IgA
(Figure 5D). Thus, the mutant M22 proteins were expressed
normally on the streptococcal surface, making them suitable
for analysis of the role of the mutated residues in binding of
C4BP (Figure 5E).
The L21A and L28A mutants had completely lost ability to
bind C4BP, a ﬁnding that may be explained by the key role
that residues in heptad position d play as core residues in a
coiled-coil. In contrast, the E24A and E31A mutants were not
Figure 5. Sequence Analysis of C4BP-Binding HVRs and Site-Specific Mutagenesis in M22
(A) Sequence logo of C4BP-binding HVRs. The logo was generated from the seven C4BP-binding HVRs aligned in Figure 1B, using WebLogo (http://
weblogo.berkeley.edu). Only regions in the HVRs corresponding to the shortest known C4BP-binding region in M22 (residues 1–39) were used to create
the logo. These regions are demarcated by the vertical hatched lines in Figure 1B. In the logo, each column in the alignment is represented by a stack of
letters, with the height of each letter proportional to the observed frequency of the corresponding residue at that position, while the overall heighto f
each stack is proportional to the sequence conservation at that position [63]. The sequence of the M4.1 HVR was included in the generation of the logo,
although it is virtually identical to M4, because the single residue difference between these two HVRs was important for the conclusion that the
different HVRs completely lack residue identities (see text). The numbering below the logo refers to residue numbers in the M22 protein and putative
coiled-coil heptads (a–g) in M22 are indicated. Asterisks show the position of four M22 residues (L21, E24, L28, and E31) analyzed by site-specific
mutagenesis.
(B) Helical wheel representation of a dimeric coiled-coil [42]. The sequence of the L21–E31 region of M22 is included, with asterisks above residues L21,
E24, L28, and E31, which were analyzed by site-specific mutagenesis and are located within the predicted coiled-coil region. The positions of residues
within putative coiled-coil heptads (a–g) are indicated.
(C–E) The four mutant M22 proteins indicated, constructed by site-specific mutagenesis, and the wild-type (wt) M22 protein, were expressed in S.
pyogenes, and the strains were analyzed for surface expression of the proteins and ability to bind C4BP. The genes encoding the proteins were present
on plasmid pLZ12Spec, carried by an M-negative strain. This M-negative strain also served as negative control. (C) and (D) show that the different
proteins were expressed normally on the bacterial surface (see text). (E) shows that mutants L21A and L28A had completely lost C4BP-binding ability,
while mutants E24A and E31A were unaffected. The results shown in (C–E) are based on three separate experiments with duplicate samples and are
presented as means 6 SD.
DOI: 10.1371/journal.ppat.0020047.g005
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Sequence Divergence in M Proteinsaffected in ability to bind C4BP, indicating that the
corresponding residues are not essential for binding of
C4BP although they probably are surface-exposed and are
relatively conserved among the sequences studied here.
The sequence logo in Figure 5A was derived from seven
HVRs known to bind C4BP (Figure 1B). This analysis was
supported by a logo derived from a larger number of HVRs,
which are not deﬁnitely known to bind C4BP but probably do
so (Figure S1A). This logo was similar to that derived from the
known C4BP-binding HVRs (Figure 5A), indicating that the
observed pattern may reﬂect an inherent property of C4BP-
binding HVRs. In contrast, a logo derived from 11 non–
C4BP-binding HVRs had another appearance (Figure S1B),
suggesting that the distribution of residues is different for
those HVRs that do not bind C4BP.
Single Amino Acid Changes in M22 that Do Not Affect
C4BP Binding Cause Major Immunological Changes
The sequence variability in the HVR of M proteins causes
antigenic variation, allowing a strain expressing one M
protein to escape recognition by antibodies directed against
other M proteins [13]. The simplest explanation for this
sequence variability is that it has arisen through gradual
accumulation of mutations, each of which causes a change in
antigenicity and at least partial escape from host immunity
(antigenic drift). It may appear intuitively obvious that
antigenic variants must be selected through this mechanism,
but it is not clear how the change of a single amino acid
residue can alter the antigenic properties of a protein to such
an extent that it can escape a polyclonal antibody response
(i.e., antibodies that probably recognize multiple epitopes).
Indeed, there is only little evidence for this hypothesis in the
literature [44,45]. We used the M22 system to analyze this
problem.
As shown in Figure 5E, the two changes E24A and E31A
had no effect on the ability of the surface-expressed M22
protein to bind C4BP. This ﬁnding made it of interest to
analyze the antigenic properties of the mutants. For this
purpose, we used an inhibition test (Figure 6A). Puriﬁed M22
protein was immobilized in microtiter wells and detected
with polyclonal mouse serum raised against the M22-N
peptide (i.e., the HVR of M22). Mouse serum was used
because the M22 protein binds to the Fc part of rabbit IgG
but does not bind mouse antibodies in such nonimmune
fashion [39]. To analyze the effect of the E24A and E31A
mutations on the antigenicity of the HVR in M22, we used
whole streptococci expressing the mutant proteins to inhibit
binding of the mouse antibodies to immobilized M22. This
experimental procedure allowed comparison of the antigenic
properties of different M22 proteins expressed on the
streptococcal surface (i.e., under physiological conditions).
Control bacteria expressed the wild-type M22 protein or no
M protein. Interestingly, a 50% reduction in binding
required ;30-fold more bacteria expressing either of the
mutant proteins, as compared to bacteria expressing wild-
type M22 protein (Figure 6B). This result was not due to
reduced surface exposure of the mutant proteins (Figure 5C
and 5D). Thus, the single amino acid changes E24A and E31A,
which do not affect the ability of M22 to bind C4BP, cause
major changes in the immunological properties of the
protein.
Discussion
In many strains of S. pyogenes, the binding of human C4BP
to M protein plays an important role for the ability of the
bacteria to evade phagocytosis [20,21]. This binding is highly
speciﬁc in spite of the sequence variability among C4BP-
binding HVRs. Indeed, the HVRs only bind C4BP among all
human plasma proteins [25,37], and C4BP only binds to M or
M-like proteins among all S. pyogenes surface proteins
[18,21,36,46]. Moreover, the only human protein that binds
to the same region in C4BP as M protein is the natural ligand
C4b [17,24]. Here, we have shown that the C4BP-binding
HVRs completely lack residue identities (i.e., they do not
share any conserved sequence motif). However, a sequence
alignment indicated that the C-terminal half of the HVRs is
more conserved than the N-terminal half, suggesting that this
part is of particular importance for binding because
interaction with the ligand may pose restraints on variability.
The hypothesis that the relatively conserved region, corre-
sponding to L21–E31 in M22, is part of the binding region is
supported by inhibition experiments with short synthetic
peptides in the M4 system [18]. However, it is difﬁcult to make
predictions about the role of different residues in this region
for the binding of C4BP, because no residue is completely
conserved.
A recent nuclear magnetic resonance study indicates that a
major part of a C4BP-binding HVR has coiled-coil structure
and the C4BP-binding site was localized to a region
corresponding to residues 13–39 in M22 [26]. However, it
has not yet been possible to conclusively determine the
structure of an HVR, so the available data must be
interpreted with caution. Our sequence analysis and muta-
genesis data support the coiled-coil model for the HVR
because replacement of the relatively conserved L21 or L28
Figure 6. Single Amino Acid Changes Not Affecting C4BP Binding Cause
Major Antigenic Changes in the HVR of M22
(A) Schematic representation of an inhibition test used to analyze the
antigenic properties of mutant M22 proteins expressed on the surface of
S. pyogenes. The test was based on the binding of mouse anti–M22-N to
pure M22 protein immobilized in microtiter wells. This binding was
inhibited with whole S. pyogenes bacteria expressing mutant M22
proteins.
(B) Ability of S. pyogenes strains expressing the M22 mutants E24A and
E31A to cause inhibition. The positive control expressed the wild-type
M22 protein and the negative control lacked M protein. As compared to
the positive control, 50% inhibition (dashed line) required ;30-fold more
bacteria expressing either of the mutant proteins. Results based on three
separate experiments with duplicate samples, presented as means 6 SD.
DOI: 10.1371/journal.ppat.0020047.g006
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Although it cannot be excluded that these Leu residues are
directly involved in binding, this result can most easily be
explained by distortion of a coiled-coil structure. In contrast,
replacement of the relatively conserved E24 and E31 residues
(which are predicted to be surface-exposed in a coiled-coil)
with Ala did not have any apparent effect on C4BP binding.
Moreover, the position occupied by E31 in M22 is occupied
by a helix-breaking Gly residue in M114. Thus, it is not clear
why E24 and E31 are relatively conserved among the C4BP-
binding M proteins. Further analysis of the role of different
residues in the HVR will require determination of the
structure of one or more HVRs in complex with C4BP.
While the predicted coiled-coil structure of the HVR still
represents a model, the structure of the M protein-binding
region in C4BP has recently been determined [47]. Moreover,
residues in C4BP implicated in binding of the M4 protein
were identiﬁed [47]. The binding region in C4BP is located in
the a chain, in which the ﬁrst two complement control
protein (CCP) modules are necessary and sufﬁcient for
binding [17,24,47]. The M protein–binding site is most likely
located at or near the intermodular interface and in a patch
on CCP2 [47]. Electrostatic interactions play a role in binding,
but other forces probably also contribute, as witnessed by the
lack of dependence on salt and pH [24,47]. Thus, much
information is available concerning the interaction between
C4BP and M protein, but these data do not provide an
explanation for the ability of C4BP to speciﬁcally bind HVRs
with very different sequences.
The extreme sequence divergence in the C4BP-binding
HVR of M protein contrasts with some well-known systems,
such as the hemagglutinin of the inﬂuenza virus, which
exhibits extensive sequence variability but nevertheless
retains some completely conserved residues that are required
for ligand binding [8–10]. Even the very variable gp120
protein of HIV-1 contains some highly conserved residues,
which have been implicated in binding to the cellular
receptor CD4 [48–50]. These comparisons raise the question
why the C4BP-binding HVRs exhibit such extensive sequence
divergence.
One possible explanation for the remarkable sequence
divergence in C4BP-binding HVRs is that M proteins have
been under stronger selective pressure for change than most
other surface proteins in pathogens, including the two viral
proteins mentioned above. However, it is difﬁcult to envisage
how selective pressure from the immune system could have
caused greater variability in S. pyogenes than in rapidly
mutating RNA viruses such as inﬂuenza virus or HIV-1. An
alternative explanation is that the C4BP-binding HVRs
employ a binding mechanism that easily permits sequence
variability. According to one interesting hypothesis, main-
chain atoms in the HVR make an important contribution to
the binding surface, a situation that would make the
interaction at least partially independent of amino acid
sequence. Binding of C4BP via main-chain atoms may also
explain why the HVRs have very different antigenic proper-
ties, although they probably have similar structure, because
antibodies preferentially contact side chains [51]. Thus, C4BP
and antibodies may bind to the HVR by different mecha-
nisms. Precedence for binding via main-chain atoms in a
variable region comes from studies of gp120 in HIV-1, in
which half of the residues that contact human CD4 do so only
through main-chain atoms [49]. Moreover, studies of Pseudo-
monas aeruginosa pilin suggest that the receptor-binding
surface may be dominated by main-chain atoms that interact
with a disaccharide on target cells [52].
Another mechanism that may contribute to the ability of
HVRs with very different sequences to bind C4BP could
involve the many charged residues in the HVRs. Although the
combined effect of these charged residues may be important
for binding, it is conceivable that the HVRs behave as if they
were saturated with charge, making them insensitive to a
single-charge substitution, as described for peptides binding
the eukaryotic protein calmodulin [53].
The appearance of antigenic variation through antigenic
drift implies that a single amino acid change may alter the
antigenic properties of a protein to such an extent that it can
at least partially escape a polyclonal antibody response. There
is only little evidence for this important hypothesis, but our
analysis of M22 variants, constructed by site-speciﬁc muta-
genesis, demonstrated that single amino acid changes, which
did not affect C4BP-binding, indeed caused a major change in
the antigenic properties of the protein. Although the
mutations analyzed here have not been identiﬁed among
clinical S. pyogenes isolates, these results support the notion
that novel antigenic types may appear through gradual
accumulation of single amino acid changes. However, the
mechanism by which a single amino acid change may cause a
major alteration in antigenic properties, without affecting
ligand-binding properties, remains unclear. One explanation
for this remarkable situation could be that a single residue
change indirectly affects the structure of all surface epitopes
without affecting the ligand-binding site [44]. Alternatively, a
polyclonal antibody response may be composed of a limited
antibody repertoire, allowing escape of immune attack also
through a limited structural change [54].
In summary, comparison of seven M proteins shows that
their C4BP-binding HVRs completely lack residue identities,
although they speciﬁcally bind to the same region in C4BP.
This sequence divergence represents a striking example of
Darwinian evolution in a microbial surface protein, which
varies to evade immune attack in infected hosts but
simultaneously must retain an important function [55].
Such extreme sequence divergence may occur also in other
ligand-binding virulence factors that are major targets for
host immunity, and it underlines the difﬁculty in identifying
conserved sequence motifs suitable for vaccine develop-
ment. Finally, the work described here is of interest for
structural biology, because it implies that microbial protein
regions lacking residue identities may adopt the same
structure, allowing them to speciﬁcally bind the same
ligand.
Materials and Methods
Bacterial strains, plasmids, and culture conditions. The S. pyogenes
strains expressing the M5, M12, M22, and M60 proteins have been
described [16,18]. All other wild-type S. pyogenes strains were reference
strains from the Center for Disease Control and Prevention, Atlanta,
GA. On the basis of the M protein expressed by these strains, they are
referred to here as M2, M4, etc., except that some of the isolates
represented allelic variants and are designated M3.1, M14.5, etc. The
M-negative S. pyogenes mutants DM5, derived from strain M5
Manfredo, and AL168mrp
 emm
 , derived from the reference M22
strain AL168, have been described [46,56]. The E. coli strains LE392,
KJ622 [57], or TG1 were used for subcloning.
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pKEJ1 is a derivative of pBR322 carrying the emm5 gene with a
restriction site for BglII at nucleotide 474 [18]. Plasmid pLZ12Spec is
an E. coli–S. pyogenes shuttle vector carrying a spectinomycin resistance
gene [58]. A derivative of pLZ12Spec carrying the emm22 gene has
been described [56].
E. coli strains were cultured in Luria-Bertani broth. S. pyogenes
strains were grown in Todd-Hewitt broth supplemented with 0.2%
yeast extract and incubated without shaking in 5% CO2 at 37 8C.
Strains of E. coli carrying derivatives of pBR322 were grown in the
presence of ampicillin (100 lg/ml). Strains carrying pLZ12Spec were
grown in the presence of spectinomycin (20 lg/ml for E. coli and 70
lg/ml for S. pyogenes).
Fusion proteins. In the M4.1–M5 and M114–M5 fusion proteins,
the region comprising the ﬁrst 45 amino acid residues of M4.1, or the
ﬁrst 53 residues of M114, is fused to residues 104–450 of M5. For
construction of genes encoding these proteins, the promoter region
and the region encoding the indicated N-terminal region of M4.1 or
M114 was ampliﬁed by PCR using chromosomal streptococcal DNA as
template. The DNA fragments were ligated into plasmid pKEJ1
digested with SalI and BglII. A similar procedure was used to prepare
constructs encoding the fusion proteins M22
31–M5 and M22
40–M5.
The construct encoding M22
39–M5 was derived from that encoding
M22
40–M5 by using the QuickChange mutagenesis kit (Stratagene, La
Jolla, California, United States). The construct encoding M22
57–M5
has been described [18]. The sequence of all clones was conﬁrmed by
DNA sequencing. For expression of fusion genes in S. pyogenes, they
were transferred to pLZ12Spec, followed by transformation into the
M-negative S. pyogenes strain DM5. Because all fusion proteins studied
here included the Fg-binding B-repeat region and the C-repeat
region of M5, the proteins could be identiﬁed by ability to bind Fg or
antiserum to the C repeats.
Site-speciﬁc mutagenesis. Site-speciﬁc mutagenesis was performed
according to Bergga ˚rd et al. (2001). The procedure employed an XhoI
site and an Mph1031 site in the emm22 gene, located at positions
corresponding to amino acids S8–N10 and Y36–L38, respectively. The
Mph1031 site was present in the wild-type emm22 gene, while the XhoI
site had been introduced by site-speciﬁc mutagenesis and caused an
amino acid change. However, this XhoI site was eliminated in the
ﬁnal construct (see below). To introduce a mutation in the region
between the two restriction sites, a plasmid carrying the emm22 gene
(with the XhoI and Mph1031 sites) was digested with XhoI and
Mph1031, followed by replacement of the deleted fragment with a
synthetic linker containing the desired sequence change. The linker
was constructed to destroy the XhoI site, thereby restoring the wild-
type sequence at that site. Due to difﬁculties during the cloning work
described here, the emm22 gene subjected to mutagenesis was not
carried on plasmid pLZ12Spec, as previously described [20], but was
transferred to pBR322. After ligation of the linkers into the cleaved
plasmid, the construct was transformed into E. coli LE392 and clones
were screened for presence of the substitution by XhoI digestion of
PCR products. Clones that were negative in this screening were
analyzed for protein expression in E. coli and veriﬁed by DNA
sequencing. The mutated emm22 genes, lacking the XhoI site, were
transferred back to pLZ12Spec to allow transformation into
streptococci. This procedure was used for construction of the
mutated genes encoding the E24A, L28A, and E31A proteins. The
gene encoding the L21A protein was generated by PCR on plasmid
pLZ12Spec carrying the emm22 gene using the QuickChange site-
speciﬁc mutagenesis kit. This change introduced a restriction site for
AlwNI, a property used to screen PCR products. Positive clones were
conﬁrmed by DNA sequencing. The pLZ12Spec derivatives encoding




Puriﬁed proteins and synthetic peptides. The M22 (Sir22) protein
was puriﬁed as described [39]. Human C4BP was puriﬁed as described
[37]. Human Fg was from American Diagnostica (Stamford, Con-
necticut, United States) and human serum IgA was from Cappel
Organon-Teknika (Turnhout, Belgium). Staphylococcal protein A
and streptococcal protein G were from Amersham Biosciences
(Uppsala, Sweden). The synthetic peptides M5–N and M22–N were
derived from the N-terminal 50 or 52 amino acid residues of the
mature forms of M5 and M22, respectively [25]. The M114-N peptide
was derived from the N-terminal 52 residues of the predicted mature
form of the M114 protein. These peptides were purchased from The
Department of Clinical Chemistry, Malmo ¨ General Hospital, Lund
University (Malmo ¨, Sweden). Each of the M5-N, M22-N, and M114-N
peptides included a C-terminal cysteine residue, not present in the
intact M protein, to allow dimerization via a disulphide bridge [25].
Dimerization was performed as described [25].
Antisera. Rabbit antiserum against a peptide derived from the C-
repeat region in M5 (anti–M5-C) was prepared as described [25]. Rat
antiserum against a synthetic peptide derived from the C-repeat
region of M4/M22 and designated anti–M22-C was prepared as
described [59]. Antiserum against the M22-N peptide was raised in
mice [21]. Rabbit anti-mouse immunoglobulins were from DakoCy-
tomation (Glostrup, Denmark).
Binding tests and inhibition tests. Binding of radiolabelled human
Fg, IgA, or C4BP to whole streptococci was analyzed as described
[46]. In brief, streptococci from overnight cultures were washed in
PBS supplemented with 0.02% NaN3 and 0.05% Tween 20 (PBSAT)
and resuspended to a concentration of 10
9 bacteria/ml. The
streptococci were diluted as indicated in a suspension of E. coli (to
provide a pellet in subsequent centrifugation steps) and incubated
with radiolabelled ligand (;14,000 cpm) at room temperature for 1
h. After washes, the radioactivity associated with each pellet was
measured in a gamma counter. To screen many S. pyogenes strains for
ability to bind C4BP (Figure 2), radiolabelled C4BP was incubated
with duplicate samples (200 ll) of bacterial suspensions containing
10
9 bacteria/ml. Each strain was analyzed at least twice with similar
results. Background binding to an M-negative strain (;3%) has been
subtracted.
Binding of rat or rabbit antibodies to whole streptococci was
analyzed essentially as described [60]. Brieﬂy, washed overnight
cultures of streptococci in PBSAT were diluted to 10
9 bacteria/ml and
samples (200 ll) were incubated for 1 h at room temperature with rat
or rabbit antiserum diluted in PBSAT. For detection of bound
antibodies, the washed bacteria were incubated with radiolabelled
protein A or protein G (;14,000 cpm in 200 ll). After washing,
radioactivity associated with each pellet was measured in a gamma
counter.
Inhibition tests with the M22-N and M114-N peptides (Figure 4B)
were performed essentially as described [25]. Brieﬂy, human C4BP
was immobilized in microtiter wells, which were blocked with PBSAT,
and radiolabelled M22 protein (;14,000 cpm/well) was added
together with a solution of unlabelled peptide to achieve a ﬁnal
concentration of 0–500 lg/ml. After incubation for 1 h at room
temperature, the wells were washed and radioactivity associated with
each well was determined.
The ability of whole streptococci to inhibit binding between pure
M22 and mouse anti-M22-N (Figure 6) was performed essentially as
described [21]. In brief, suspensions of whole washed bacteria, diluted
as indicated, were prepared in mouse anti–M22-N (diluted 200-fold),
and added to microtiter wells coated with M22 protein (50 ll, 1 lg/
ml). After washings (to remove bacteria and mouse antibodies not
bound to the immobilized M22), mouse antibodies bound to the
immobilized M22 protein were detected with rabbit anti-mouse Ig
and radiolabelled protein G. A control with preimmune mouse serum
did not show any binding to M22, showing that the binding of the
anti–M22-N serum was speciﬁc. Of note, mouse C4BP does not bind
to M22 and should not affect the analysis [17,37].
Afﬁnity chromatography. Chromatography of human serum using
immobilized peptides was performed essentially as described
[25,37]. Brieﬂy, 5 mg of dimerized peptide (M5-N, M22-N, or
M114-N) was immobilized in a 1 ml HiTrap column containing N-
hydroxysuccinimide–activated agarose beads (Amersham Pharmacia
Biotech, Little Chalfont, United Kingdom). Human serum (5 ml)
diluted 5-fold in TBS (20 mM Tris, 0.15 M NaCl [pH 7.4]) was
applied to the column, and after ten washes with TBS (1 ml), bound
proteins were eluted, dialyzed against TBS, and analyzed by SDS-
PAGE.
Sequence analysis. A multiple sequence alignment of C4BP-
binding HVRs (Figure 1B, upper part) was constructed with the
CLUSTALW [61] algorithm with the BLOSUM62 [62] residue
substitution score matrices. The shortest known C4BP-binding region
of each protein, as determined with fusion proteins or synthetic
peptides [18,25], was included in the alignment. Note that the
sequence of the M4 HVR shown here is the wild-type sequence and
differs from the sequence in the previously characterized M4-N
peptide at one position because the R32 residue was substituted for a
Lys in the peptide for technical reasons [25]. The C4BP-binding HVRs
of the M4.1 and M114 proteins (Figure 1B, lower part) were aligned
manually to the other sequences. The sequence logos in Figure 5A
and Figure S1 were generated using WebLogo (http://weblogo.
berkeley.edu) [63]. A coiled-coil prediction (Figure 5A) was generated
using the COILS algorithm [64].
Other methods. Radiolabelling of proteins with carrier-free
125I
(Amersham Pharmacia Biotech) was performed with the chloramine-
T method [65] or a modiﬁed lactoperoxidase method [66].
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Figure S1. Sequence Logos Derived from HVRs in M Proteins
The sequence logo in Figure 5A was derived from seven HVRs known
to bind C4BP (Figure 1B). To analyze additional C4BP-binding HVRs,
we compared the HVRs in M proteins of all OF
þ strains studied here.
Although molecular analysis has not conclusively shown that these
HVRs bind C4BP, it seems likely that they do because all OF
þ strains
bind C4BP (Figure 2, upper panel), and because the ability to bind
C4BP has been attributed to the M protein HVR in all OF
þ strains
analyzed [18,25] (this paper). To analyze non–C4BP-binding HVRs, we
used data for the 11 nonbinding strains included in Figure 2, lower
panel.
(A) Logo derived from the HVRs in 47 M proteins expressed by OF
þ
C4BP-binding strains of different serotype (i.e., all strains in upper
panel of Figure 2). This logo is similar to that derived from known
C4BP-binding HVRs (Figure 5A). In particular, the C-terminal half is
less variable than the N-terminal half and includes two dominating
Leu residues and a preponderance of negatively charged residues.
(B) Logo derived from 11 non–C4BP-binding HVRs. The appearance
of this logo is different from that of the logos in Figures 5A and (A).
Although dominating Leu residues are seen also in this logo (most
likely reﬂecting a coiled-coil structure), the variability is similar in
both halves of the logo, and it is not clear that the C-terminal half
contains a preponderance of negatively charged residues. The logos
must be compared with caution, but this analysis suggests that the
distribution of residues is different for those HVRs that bind C4BP
and those that do not.
To construct these logos, residues 1–50 of the indicated HVRs were
aligned using ClustalW. The two most conserved Leu residues were
used to manually align these HVRs to those analyzed in Figure 5A.
Note that the logos shown here only include the 39 residues
predicted to correspond to the C4BP-binding region analyzed in
Figure 5A.
Found at DOI: 10.1371/journal.ppat.0020047.sg001 (303 KB PDF).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
bers for the genes and gene products discussed in this paper are C4BP
a-chain (M31452), M2 (EmmL2.1) (X61276), M4 (Arp4) (X15198), M22
(Sir22) (X75750), M60(Arp60) (Z22751), and PrtH (M29398). Sequen-
ces for the HVRs of the M4.1 and M114 proteins, and sequences for M
protein HVRs of the strains analyzed in Figure 2, are available at the
Centers for Disease Control Streptococcus pyogenes emm sequence
database (http://www.cdc.gov/ncidod/biotech/strep/doc.htm).
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